| abstract |
In particular, compositions and methods for targeting E3 ligase are disclosed herein. In one aspect, it is a target proteolytic agent comprising 1) a target protein ligase and 2) an E3 ubiquitin ligase ligase, wherein the E3 ubiquitin ligase is a human RNF4 or a human RNF114. In one aspect, a pharmaceutical composition comprising a compound described herein comprising an embodiment and a pharmaceutically acceptable excipient is provided. |